Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.
Christina A MetcalfChloe E PageBrianna O S StockerRachel L JohnsonKorrina A DuffyMary D SammelJames LougheadC Neill EppersonPublished in: Gynecologic oncology (2024)
Lisdexamfetamine improved both subjective and objective measures of attention and working memory and could offer women experiencing cognitive difficulties post-risk-reducing salpingo-oophorectomy an alternative therapeutic option.
Keyphrases
- working memory
- breast cancer risk
- transcranial direct current stimulation
- attention deficit hyperactivity disorder
- clinical trial
- replacement therapy
- study protocol
- open label
- phase iii
- polycystic ovary syndrome
- type diabetes
- randomized controlled trial
- sleep quality
- pregnant women
- phase ii
- pregnancy outcomes
- skeletal muscle